Contrary to the most commonly cited cost, a new study at JAMA Internal Medicine finds that the cost of developing a cancer drug is around $650 million and that companies typically fully recover that cost within a couple of years after approval.
Call9, which connects patients to on-demand emergency physicians and currently is used by skilled nursing facilities, has dialed up investors for a fresh $24 million in capital.
98point6 raises a hot $19.5 million from feverish investors. I am not sure what it does but the geniuses who wrote the press release say the company has an "audacious vision". It uses "deep technology" (on the ocean floor?) to do something related to continuity of care at a "massively lower cost than anything in the market today" (I didn't know cost had mass.) It is not a good sign when you can't tell in the first sentence or two of a press release what a company actually does. These investors are truly delirious.
Cardinal Analytx, which will use artificial intelligence and machine learning to predict which patients will be high cost, gathers $6.1 million in fresh funding.
Large benefit consulting firm Mercer says that health benefit cost trend for employers in 2018 will be 4.3%, after benefit changes, with drug costs continuing to disproportionately affect that trend.
A survey from Health Catalyst finds that most providers think their EHR is providing a poor or worse return on investment and only 10% say they are getting a positive return.
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at khroche@healthy-skeptic.com.
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at khroche@healthy-skeptic.com.